菲鹏旗下子公司，守望200亿美金未来五年市场

Core Insights - The release of DeepConformer2.0 marks a significant advancement in protein dynamic conformation prediction, becoming the first model in China to achieve this for complex proteins, with a projected market size of $20 billion by 2030 [1][10][15] - The upgrade from single-chain to complex protein prediction enhances the model's accuracy, surpassing even the capabilities of AlphaFold, which is expected to win a Nobel Prize in 2024 [3][5] Company Developments - The company, Fipeng Shuhui, has showcased its unique "AI+MD" technology at the AIBC, emphasizing its dual-core technology that combines AI predictions with reliable MD validation [11][15] - Fipeng Shuhui's technology has been successfully applied in various projects, including enzyme specificity and thermal stability modifications, RNA aptamer design, and antibody design, indicating a clear path to commercialization [15] Market Potential - The AI and biomedicine sectors are experiencing rapid growth, with Fipeng Shuhui's market projections indicating a potential $20 billion market by 2031, covering areas such as IVD and precision therapy, new drug development, and synthetic biology [10][15] - Specific market segments include $2-3 billion for antigen/antibody development and molecular diagnostics, $3.5-4.5 billion for new drug development, and $9-10 billion for synthetic biology applications [10][15]